Have a feature idea you'd love to see implemented?
Let us know!
CLSD Clearside Biomedical Inc
Price (delayed)
$1.02
Market cap
$77.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.45
Enterprise value
$113.45M
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS
Highlights
CLSD's gross margin is up by 34% YoY
The EPS has grown by 26% year-on-year and by 10% since the previous quarter
CLSD's equity has dropped by 171% year-on-year and by 23% since the previous quarter
CLSD's debt is up by 20% year-on-year and by 5% since the previous quarter
Key stats
What are the main financial stats of CLSD
Market
Valuations
Earnings
Shares outstanding
75.84M
Market cap
$77.36M
Enterprise value
$113.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
9.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.73
Revenue
$7.7M
EBIT
-$31.88M
EBITDA
-$31.71M
Free cash flow
-$19.6M
Per share
Balance sheet
Liquidity
EPS
-$0.45
Free cash flow per share
-$0.26
Book value per share
-$0.47
Revenue per share
$0.1
TBVPS
$0.39
Total assets
$29.16M
Total liabilities
$63.95M
Debt
$49.97M
Equity
-$34.79M
Working capital
$19.52M
Debt to equity
-1.44
Current ratio
4.49
Quick ratio
4.36
Net debt/EBITDA
-1.14
Margins
Efficiency
Dividend
EBITDA margin
-411.7%
Gross margin
100%
Net margin
-413.8%
Operating margin
-339.4%
Return on assets
-92.9%
Return on equity
N/A
Return on invested capital
-63%
Return on capital employed
-135.3%
Return on sales
-413.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLSD stock price
How has the Clearside Biomedical stock price performed over time
Intraday
-2.86%
1 week
-2.86%
1 month
-22.73%
1 year
7.37%
YTD
-12.82%
QTD
-19.69%
Financial performance
How have Clearside Biomedical's revenue and profit performed over time
Revenue
$7.7M
Gross profit
$7.7M
Operating income
-$26.15M
Net income
-$31.88M
Gross margin
100%
Net margin
-413.8%
CLSD's net margin has surged by 75% year-on-year and by 7% since the previous quarter
The operating margin has soared by 75% YoY and by 6% from the previous quarter
CLSD's gross margin is up by 34% YoY
The company's net income rose by 15% YoY and by 4.7% QoQ
Growth
What is Clearside Biomedical's growth rate over time
Valuation
What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
N/A
P/S
9.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.73
The EPS has grown by 26% year-on-year and by 10% since the previous quarter
CLSD's equity has dropped by 171% year-on-year and by 23% since the previous quarter
The P/S is 63% below the 5-year quarterly average of 26.9 and 15% below the last 4 quarters average of 11.7
The revenue has grown by 2.4% from the previous quarter
Efficiency
How efficient is Clearside Biomedical business performance
The return on sales has surged by 75% year-on-year and by 7% since the previous quarter
Clearside Biomedical's return on invested capital has increased by 38% YoY and by 13% QoQ
The company's return on assets fell by 6% YoY
Dividends
What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLSD.
Financial health
How did Clearside Biomedical financials performed over time
The company's total assets is 54% lower than its total liabilities
The total liabilities is up by 35% YoY and by 2.8% from the previous quarter
The current ratio has contracted by 15% YoY and by 11% from the previous quarter
CLSD's equity has dropped by 171% year-on-year and by 23% since the previous quarter
The debt to equity has soared by 56% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.